Veracyte, Inc.
VCYT- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- SEC CIK
- 0001384101
In the last 90 days, Veracyte, Inc. insiders filed 0 open-market purchases and 9 sales; 373 institutions reported holding it in 13F filings for Q2 2026, worth $5.23B in total; ARK Invest is the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:47 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Feb 24, 2025 | Jan 8, 2024 | Feb 22, 2023 | Feb 28, 2022 |
| Revenue | $517.1M | $445.8M | $361.1M | $296.5M | $219.5M |
| Gross profit | $362.5M | $298.1M | – | – | – |
| Research and development | $70.8M | $69.3M | $57.3M | $40.6M | $29.8M |
| Selling, general and administrative | $110.8M | $110.6M | $86.2M | $76.5M | $101.4M |
| Operating income | $57.8M | $16.1M | -$85.8M | -$41.1M | -$81.9M |
| Income tax | $1.85M | $1.61M | -$2.21M | $133.0K | -$6.09M |
| Net income | $66.4M | $24.1M | -$74.4M | -$36.6M | -$75.6M |
| EPS, basic | $0.84 | $0.32 | $-1.02 | $-0.51 | $-1.11 |
| EPS, diluted | $0.82 | $0.31 | $-1.02 | $-0.51 | $-1.11 |
| Weighted shares, basic | 78.6M | 76.5M | 72.6M | 71.5M | 67.9M |
| Weighted shares, diluted | 80.6M | 78.2M | 72.6M | 71.5M | 67.9M |
| Margins and growth | |||||
| Gross margin | 70.1% | 66.9% | – | – | – |
| Operating margin | 11.2% | 3.6% | -23.8% | -13.9% | -37.3% |
| Net margin | 12.8% | 5.4% | -20.6% | -12.3% | -34.4% |
| Revenue growth, year over year | +16.0% | +23.5% | +21.8% | +35.1% | +86.8% |
| Net income growth, year over year | +174.9% | – | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Feb 24, 2025 | Jan 8, 2024 | Feb 22, 2023 | Feb 28, 2022 |
| Cash and equivalents | $362.6M | $239.1M | $216.5M | $154.2M | $173.2M |
| Accounts receivable | $44.7M | $46.5M | $40.4M | $44.0M | $41.5M |
| Inventory | $20.5M | $21.8M | $16.1M | $14.3M | $11.2M |
| Total current assets | $488.4M | $372.3M | $285.6M | $248.6M | $243.1M |
| Property, plant and equipment | – | – | – | $17.7M | $15.1M |
| Goodwill | $767.2M | $745.8M | $703.0M | $695.9M | $707.9M |
| Intangible assets | $89.1M | $102.3M | $88.6M | $174.9M | $202.7M |
| Total assets | $1.41B | $1.30B | $1.11B | $1.16B | $1.19B |
| Accounts payable | $4.59M | $8.63M | $12.9M | $11.9M | $12.4M |
| Short-term debt | – | – | – | $0 | $1.13M |
| Total current liabilities | $59.9M | $78.6M | $61.2M | $62.6M | $64.2M |
| Long-term debt | – | – | – | – | $0 |
| Total liabilities | $96.4M | $124.1M | $70.8M | $81.2M | $91.3M |
| Shareholders' equity | $1.31B | $1.18B | $1.04B | $1.08B | $1.10B |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Feb 24, 2025 | Jan 8, 2024 | Feb 22, 2023 | Feb 28, 2022 |
| Operating cash flow | $136.3M | $75.1M | $44.2M | $7.54M | -$31.6M |
| Capital expenditures | $9.68M | $11.3M | $9.96M | $8.55M | $5.38M |
| Free cash flow | $126.6M | $63.8M | $34.3M | -$1.01M | -$37.0M |
| Depreciation and amortization | $21.4M | $23.5M | $27.2M | $25.9M | $19.6M |
| Stock-based compensation | $43.6M | $36.2M | $33.1M | $26.7M | $22.5M |
| Investing cash flow | -$9.21M | -$56.3M | $15.1M | -$29.4M | -$739.2M |
| Financing cash flow | -$4.22M | $4.90M | $2.84M | $3.49M | $596.3M |
| Net change in cash | $123.6M | $23.3M | $62.3M | -$18.9M | -$176.0M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 8.4% | 8.1% | 9.2% | 9.0% | 10.3% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.